Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Denufosol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 known ✓ | P41231 | 13/20 | 1.00 |
| ▸ | P2RY4 | P51582 | 6/20 | 1.00 |
| ▸ | P2RY6 | Q15077 | 8/20 | 0.81 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | GLA | P06280 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | ST6GAL1 | P15907 | 3/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29798782 | 0.90 | P2RY2 (0.86) | P2RY2P2RY4P2RY6 | |
| SCHEMBL30111010 | 0.90 | P2RY2 (0.86) | P2RY2P2RY4P2RY6 | |
| Denufosol SCHEMBL24414847 | 0.89 | P2RY2 (1.00) | P2RY2P2RY4P2RY6 | |
| Denufosol SCHEMBL30480354 | 0.89 | P2RY2 (1.00) | P2RY2P2RY4P2RY6 | |
| Denufosol SCHEMBL15108954 | 0.89 | P2RY2 (1.00) | P2RY2P2RY4P2RY6 | |
| Denufosol SCHEMBL22127329 | 0.89 | P2RY2 (1.00) | P2RY2P2RY4P2RY6 | |
| Denufosol SCHEMBL561652 | 0.89 | P2RY2 (0.98) | P2RY2P2RY4P2RY6 | |
| Deoxycytidine Triphosphate SCHEMBL1331708 | 0.86 | P2RY2 (0.74) | P2RY2P2RY4P2RY6TSHRGLA | |
| Deoxycytidine Triphosphate SCHEMBL28165219 | 0.86 | P2RY2 (0.74) | P2RY2P2RY4P2RY6TSHRGLA | |
| Cytarabine 5'-Phosphate SCHEMBL25290865 | 0.84 | P2RY2 (0.89) | P2RY2P2RY4P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 270 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144743-A1 | COMPOUNDS | TMEM16A LIMITED (GB) | 2026-05-28 | — | — | US | disclosed |
| US-20260144674-A1 | Apparatus and Methods for Drug Delivery Using Microneedles | CLEARSIDE BIOMEDICAL, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| EP-2819670-B1 | PHARMACEUTICAL COMPOSITION AND ADMINISTRATION THEREOF | VERTEX PHARMA (US) | 2026-05-20 | — | — | EP | disclosed |
| US-12606614-B2 | Human FcRn-binding modified antibodies and methods of use | HOFFMANN-LA ROCHE INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-20260103527-A1 | TIE2-BINDING AGENTS AND METHODS OF USE | GENENTECH INC (US) | 2026-04-16 | — | — | US | disclosed |
| EP-3749386-B1 | SYSTEMS, KITS AND METHODS FOR LOADING AND DELIVERING A SMALL VOLUME DOSE FROM A SYRINGE | ICON BIOSCIENCE INC (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-4003977-B1 | PYRIDINE DERIVATIVES AS CALCIUM-ACTIVATED CHLORIDE CHANNEL MODULATORS | TMEM16A LTD (GB) | 2026-04-15 | — | — | EP | disclosed |
| EP-4724079-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION | Stealth BioTherapeutics Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-2841109-B1 | PRODRUGS OF HYDROXYL-COMPRISING DRUGS | ASCENDIS PHARMA AS (DK) | 2026-04-15 | — | — | EP | disclosed |
| EP-4699655-A2 | COMPOUNDS | TMEM16A LIMITED (GB) | 2026-02-25 | — | — | EP | disclosed |
| US-20220098164-A1 | MODULATORS OF TMEM16A FOR TREATING RESPIRATORY DISEASE | TMEM16A LIMITED (GB) | 2022-03-31 | — | — | US | disclosed |
| CN-114230571-A | Solid forms of isoquinolinones, methods of making, compositions containing, and methods of use thereof | 无限药品股份有限公司 | 2022-03-25 | — | — | CN | disclosed |
| EP-3964507-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Infinity Pharmaceuticals, Inc. (US) | 2022-03-09 | — | — | EP | disclosed |
| WO-2020249956-A9 | MODULATORS OF TMEM16A FOR TREATING RESPIRATORY DISEASE | TMEM16A LIMITED (GB) | 2022-03-03 | — | — | WO | disclosed |
| US-20220040095-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2022-02-10 | — | — | US | disclosed |
| US-20220041707-A1 | ANTIBODY THAT BINDS TO VEGF AND IL-1BETA AND METHODS OF USE | HOFFMANN-LA ROCHE INC. (US) | 2022-02-10 | — | — | US | disclosed |
| US-20220041684-A1 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 LTD. (GB) | 2022-02-10 | — | — | US | disclosed |
| WO-2022026863-A2 | CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) MODULATORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | EMORY UNIVERSITY (US) | 2022-02-03 | — | — | WO | disclosed |
| US-20220031679-A1 | PHARMACEUTICAL COMPOSITIONS OF 3-(6-(1-(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL) BENZOIC ACID AND ADMINISTRATION THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-02-03 | — | — | US | disclosed |
| CN-110177527-B | Device and method for adjusting insertion depth of needle for medicament delivery | 科尼尔赛德生物医学公司 | 2022-02-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144743-A1 | COMPOUNDS | CACNA1E, TMEM109, CACNA1C | P2RY2 1276/4885P2RY4 2287/4885P2RY6 1575/4885 |
| US-20260144674-A1 | Apparatus and Methods for Drug Delivery Using Microneedles | PROKR2, SLC10A2, GLP1R | P2RY2 1203/4885P2RY4 1908/4885P2RY6 2623/4885 |
| US-20220098164-A1 | MODULATORS OF TMEM16A FOR TREATING RESPIRATORY DISEASE | TMEM109, CFTR, TMEM120A | P2RY2 1241/4885P2RY4 1983/4885P2RY6 1879/4885 |
| US-20220031679-A1 | PHARMACEUTICAL COMPOSITIONS OF 3-(6-(1-(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL) BENZOIC ACID AND ADMINISTRATION THEREOF | CFTR, GLI2, GPR39 | P2RY2 169/4885P2RY4 241/4885P2RY6 143/4885 |
| US-20260103527-A1 | TIE2-BINDING AGENTS AND METHODS OF USE | TIE1, KDR, FLT1 | P2RY2 2700/4885P2RY4 3816/4885P2RY6 3571/4885 |
| US-12606614-B2 | Human FcRn-binding modified antibodies and methods of use | FCGR3B, FCGR2A, FCGR1A | P2RY2 1073/4885P2RY4 781/4885P2RY6 1280/4885 |
| US-20220040095-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | P2RY2 274/4885P2RY4 478/4885P2RY6 366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.